Protocol Number: 07-I-0033

Title:

Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

Number:

07-I-0033

Summary:

This study will examine the causes of immune disorders affecting white blood cells, which defend against infections and will try to develop better means of diagnosis and treatment of these immune disorders.

Patients known to have or suspected of having increased susceptibility to infections and their blood relatives may be eligible for this study, at the discretion of the principal investigator. Patients and family members may undergo the following procedures:

-Personal and family medical history.

-Physical examination and blood and urine tests.

-Studies of breathing function (pulmonary function testing)

-Dental examination.

-Eye examination.

-Microscopic examination of saliva, wound drainage or tissues removed for medical reasons for cell, hormone or DNA studies.

In addition, patients may be asked permission for investigators to obtain their medical records, previous test results, or radiographic studies and to undergo imaging studies, such as a chest X-ray, CT scan or MRI scan.

Sponsoring Institute:

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Participants currently recruited/enrolled

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): None

Eligibility Criteria:

INCLUSION CRITERIA:

Inclusion Criteria for Patients

1. Patients known to have, or suspected of having an infection susceptibility will be eligible for enrollment.

2. Patients with known or suspected infections will also be eligible in order to identify the microbiologic cause of the infection, identify the extent of infection, or determine the proper course of treatment. There will be no limit as to age, sex, race or disability.

3. Patients must have a primary physician outside of the NIH and may be required to submit a letter from their physician that documents their relevant health history.

4. The patient or the patient's guardian will be willing and capable of providing informed consent after initial counseling by clinical staff. Separate consent forms for all interventional procedures will be obtained after explanation of the specific procedure.

5. Women of childbearing potential, or who are pregnant or lactating, may be eligible. Interventions in pregnant or lactating women will minimize as much as possible risks to the fetus/infant but will follow state of art evaluation and therapy. Should a woman become pregnant or suspect she may be pregnant while participating in this study, she should inform the study staff and her primary care physician immediately.

6. Patients must agree to have blood stored for future studies of the immune system and/or other medical conditions.

7. Patients may be concurrently enrolled on other protocols as long as the Principal Investigator is informed.

Inclusion Criteria for Healthy Blood Relatives of Patients:

1. Healthy blood relatives of patients known to have or suspected of having an infection susceptibility will be eligible for enrollment only if they have a sick relative who is enrolled on this protocol as a patient.

2. There will be no limit as age, sex, race or disability.

3. Relatives or the minor relative's guardian must be willing and capable of providing informed consent after initial counseling by clinical staff.

4. Participating relatives agree to have blood stored for future studies of the immune system and/or other medical conditions.

EXCLUSION CRITERIA:

1. A well understood acquired abnormality which leads to infection susceptibility, such as HIV, cytotoxic chemotherapy, or active malignancy may be adequate explanation for the infection diathesis. These may be grounds for exclusion if, in the opinion of the investigators, the presence of such disease process interferes significantly with evaluation (applicable to patients and their blood relatives).

2. Severe or uncommon infections or syndromes often require highly specialized teams and institutions. Some referred cases will not be able to be handled appropriately at the NIH and may be deemed ineligible for admission, as determined by the Principal Investigator.

Special Instructions:

Currently Not Provided

Keywords:

Bacteria

Fungi

Mycobacteria

Immune

Genetics

Recruitment Keyword(s):

Infection Susceptibility

Recurrent Infections

Immune Disorders

Condition(s):

Immune Disorders

Chronic Granulomatous Disease

Genetic Immunological Deficiencies

Hyperimmunoglobulin-E Recurrent Infection Syndrome

Recurrent Infections

Investigational Drug(s):

None

Investigational Device(s):

None

Intervention(s):

None

Supporting Site:

National Institute of Allergy and Infectious Diseases

Contact(s):

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citation(s):

Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000 Dec;11(4):321-33.

Fleisher TA, Straus SE, Bleesing JJ. A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome. Curr Allergy Asthma Rep. 2001 Nov;1(6):534-40.

Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, Miller JA, O'Connell AC, Puck JM. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med. 1999 Mar 4;340(9):692-702.

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 09/16/2008